Nexgel

NexGel, Inc. engages in the manufacture of polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The company was founded on January 13, 2009 and is headquartered in Langhorne, PA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nexgel reports record revenue in Q2 2024, anticipates strong growth

Nexgel's Q2 2024 performance reflects robust revenue growth driven by strategic acquisitions and expansion efforts.
Despite short-term challenges in capacity expansion, the company's financial outlook remains positive with strong revenue guidance.
Opportunities from new partnerships and product launches position Nexgel for continued growth and market success.

Nexgel reports record Q3 earnings, eyes growth through strategic initiatives

Nexgel's Q3 2024 showcased robust financial performance with record revenue and improved margins.
Strategic acquisitions, partnerships, and growth initiatives position Nexgel for continued success.
While challenges like sustaining growth and managing costs exist, opportunities for expansion and profitability are promising.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NexGel, Inc. engages in the manufacture of aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The company was founded on January 13, 2009 and is headquartered in Langhorne, PA.

NEXGEL (NASDAQ:NXGL) has announced positive results from its proof-of-concept study on idiclofenac hydrogel patches designed to treat pain caused by arthritis, joint pain, muscle aches and more. The Langhorne, Pennsylvania-based company said the study compared its diclofenac hydrogel patches with the leading commercially available topical treatment, assessing the formulations, skin retention and permeation of the products through the skin.

NEXGEL studies diclofenac hydrogel patches as new pain medication delivery method

NEXGEL (NASDAQ:NXGL) said it has developed a new hydrogel eye patch to treat amblyopia, a type of poor vision that typically occurs in one eye but can occur in both. The condition is also called lazy eye.

NEXGEL develops hydrogel patch to treat lazy eye; works better for younger children

LANGHORNE, Pa., Oct. 04, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced that Adam Levy, CEO, will participate at the Dawson James Securities 7th Annual Small Cap Growth Conference in Jupiter, Florida and the LD Micro Main Event XV Conference in Los Angeles, California in October 2022.

NEXGEL to Participate in Upcoming Investor Conferences in October 2022

Patients Treated with SilverSeal Experienced Significantly Less Scarring and Improved Skin Functionality Following Surgical Incision

SAGE Journals Publishes New Data Revealing NEXGEL's SilverSeal Hydrogel Dressing Improves Postsurgical Scarring

LANGHORNE, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that the Company has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board.

NEXGEL Appoints Dr. Leonard Nelson and Dr. Neil Chesen to Scientific Advisory Board

LANGHORNE, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced that Adam Levy, CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held on September 12th – 14th at the Lotte New York Palace Hotel in New York, NY.

NEXGEL to Present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022

The Company's Proprietary Hydrogel Technology Protects Lower Lashes and Allows for Gentle Removal

NEXGEL Launches MEDAGEL Hydroliner Pro Pads for Eyelash Protection During Cosmetic Extensions Service

For Every Two Boxes of SilverSeal ® Purchased, One i s Donated to Those Suffering in Ukraine

NEXGEL and Partners for World Health Join Forces to Support Humanitarian Relief Efforts in Ukraine and Around the World

eFFECTOR Therapeutics Inc

Invacare

TRACON Pharmaceuticals

U.S. crude oil futures traded higher by over 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.

4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And More

Langhorne, Pennsylvania--(Newsfile Corp. - June 1, 2022) - NEXGEL, Inc. (NASDAQ: NXGL) (NASDAQ: NXGLW) ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced that Adam Levy, CEO, will present at the LD Micro Invitational XII being held on June 7 - 9 at the Four Seasons Westlake Village in Westlake Village, CA.Mr. Levy is scheduled to present on Wednesday, June 8, at 10:30AM Pacific Daylight Time and...

NEXGEL to Present at the LD Micro Invitational XII on June 8, 2022

First quarter 2022 revenue increased 48% YoY to $396 Thousand Company launched two new consumer OTC products using its HYDROGEL Technology: The MEDAGEL ClearComfort Hydrogel Patch and The MEDAGEL Bug Bite Relief Patch LANGHORNE, Pa., May 12, 2022 /PRNewswire/ -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the first quarter ended March 31, 2022.

NEXGEL Reports First Quarter 2022 Financial Results

Management will host a conference call at 4:30 PM/ET on the same day LANGHORNE, Pa. , May 9, 2022 /PRNewswire/ -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that it will report its financial and operating results for the first quarter of 2022 after the market closes on May 12, 2022.

NEXGEL to Report its First Quarter 2022 Financial and Operating Results on May 12, 2022

LANGHORNE, Pa. , April 28, 2022 /PRNewswire/ -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, CEO of NEXGEL, will participate at the Planet MicroCap Showcase 2022 being held in person on May 3-5, 2022 at the Bally's Hotel & Casino in Las Vegas, NV.

NEXGEL to Present at the Planet MicroCap Showcase 2022 in Las Vegas on Wednesday, May 4, 2022

LANGHORNE, Pa. , March 24, 2022 /PRNewswire/ -- NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer of NEXGEL, will participate in the Maxim Group 2022 Virtual Growth Conference to be held virtually on March 28-30, 2022.

NEXGEL to Present at Maxim Group's 2022 Virtual Growth Conference

Full year 2021 revenue increased 130% YoY to $1.55 million As of December 31, 2021, the Company had $13.35 million in cash LANGHORNE, Pa., March 21, 2022 /PRNewswire/ -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the fourth quarter and full year periods ended December 31, 2021.

NEXGEL Reports Fourth Quarter and Full Year 2021 Financial Results

-  Management will host a conference call at 4:30 p.m. ET on the same day - LANGHORNE, Pa.

NEXGEL to Report its Fourth Quarter and Full Year 2021 Financial and Operating Results on March 21, 2022

LANGHORNE, Pa., Feb. 15, 2022 /PRNewswire/ --  NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the launch of its MEDAGEL Bug Bite Relief Patch.

NEXGEL Announces Launch of MEDAGEL Bug Bite Relief Patch

NexGel manufactures hydrogels for use in diagnostics, drug delivery, wound care and cosmetics.

NexGel: Old Wine In A New Bottle

The stock price of NEXGEL (NASDAQ: NXGL) increased by 11.95% today. This is why it happened.

NEXGEL Stock (NXGL): Why The Price Went Up Today

LANGHORNE, Pa., Jan. 12, 2022 /PRNewswire/ --  NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the launch of its MEDAGEL ClearComfort Hydrogel Patch.

NEXGEL Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch

LANGHORNE, Pa., Jan. 10, 2022 /PRNewswire/ --  NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetic, today is providing shareholders with a 2021 year in review.

NEXGEL Provides 2021 Year in Review

LANGHORNE, Pa., Jan. 4, 2022 /PRNewswire/ -- NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today announced that Adam Levy, Chief Executive Officer of NEXGEL, will participate in the H.C.

NEXGEL to Present at H.C. Wainwright's Bioconnect Conference

LANGHORNE, Pa., Dec. 27, 2021 /PRNewswire/ -- NexGel, Inc. ("NEXGEL" or the "Company") (NASDAQ: NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today announced the closing of its previously announced initial public offering of 2,585,000 shares of its common stock and accompanying warrants to purchase up to 2,585,000 shares of common stock.

NexGel, Inc. Announces Closing of $14.2 Million Initial Public Offering

LANGHORNE, Pa., Dec. 21, 2021 /PRNewswire/ -- NexGel, Inc. ("NexGel" or the "Company") (Nasdaq:NXGL, NXGLW), a manufacturer of high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics, today announced the pricing of its initial public offering of 2,585,000 shares of its common stock and accompanying warrants to purchase up to 2,585,000 shares of common stock.

News for Nexgel Stock (NXGL)